Table 1.
Expression levels of the Alu 111‐bp and Alu 260‐bp fragments in patients with different clinical characteristics (presented as mean ± SD; ΔCt)
| Factors | 111 | 260 | 111 | 260 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre‐NCT | Post‐first NCT | Post‐NCT | Pre‐NCT | Post‐first NCT | Post‐NCT | P value1 | P value2 | P value1 | P value2 | |
| Total | ||||||||||
| Age (y) | <.0001 | .6394 | <.0001 | .6577 | ||||||
| <50 | 7.773 ± 1.655 | 6.178 ± 1.889 | 6.603 ± 1.676 | 9.207 ± 1.394 | 7.583 ± 1.510 | 7.595 ± 1.681 | ||||
| ≥50 | 7.865 ± 1.601 | 6.984 ± 2.082 | 6.193 ± 1.651 | 9.031 ± 1.608 | 8.407 ± 1.755 | 7.329 ± 1.708 | ||||
| HER‐2 status | <.0001 | .3984 | <.0001 | .3063 | ||||||
| Negative | 7.849 ± 1.693 | 6.765 ± 2.096 | 6.538 ± 1.652 | 9.124 ± 1.557 | 8.195 ± 1.835 | 7.606 ± 1.840 | ||||
| Positive | 7.780 ± 1.494 | 6.382 ± 1.910 | 6.085 ± 1.674 | 9.082 ± 1.450 | 7.771 ± 1.392 | 7.165 ± 1.371 | ||||
| Molecular subtype | .0002 | .8669 | .0005 | .1482 | ||||||
| Hormone + HER‐2–/+ | 7.859 ± 1.549 | 6.566 ± 1.953 | 6.344 ± 1.610 | 9.051 ± 1.630 | 7.850 ± 1.604 | 7.298 ± 1.648 | ||||
| TNBC | 7.533 ± 1.971 | 6.959 ± 2.401 | 6.845 ± 1.600 | 9.487 ± 1.130 | 8.781 ± 2.067 | 8.092 ± 1.815 | ||||
| Hormone‐HER‐2+ | 8.100 ± 1.573 | 6.462 ± 2.114 | 5.737 ± 2.171 | 8.839 ± 1.195 | 8.099 ± 1.420 | 7.360 ± 1.762 | ||||
| Lymph node | <.0001 | .4929 | <.0001 | .3538 | ||||||
| ≤2 | 7.483 ± 1.929 | 6.724 ± 2.229 | 6.235 ± 1.758 | 9.178 ± 1.583 | 8.290 ± 1.838 | 7.560 ± 1.701 | ||||
| >2 | 8.114 ± 1.242 | 6.545 ± 1.862 | 6.493 ± 1.591 | 9.051 ± 1.462 | 7.832 ± 1.549 | 7.351 ± 1.696 | ||||
P value1: time.
P value2: different clinical characteristics.